Table 1.
Baseline characteristics of stable CHD patients receiving Xuefu Zhuyu granules or placebo.
| Placebo group (n = 20) | Xuefu Zhuyu group (n = 20) | All (n = 40) | |
|---|---|---|---|
| Course of disease (months) | 52.13 ± 38.12 | 69.78 ± 51.69 | 60.72 ± 45.48 |
| Demographics | |||
| Age (years) | 60.00 ± 6.63 | 56.05 ± 9.86 | 58.03 ± 8.53 |
| Male, n (%) | 15 (75) | 15 (75) | 30 (75) |
| Female, n (%) | 5 (25) | 5 (25) | 10 (25) |
| Race | |||
| Han | 19 | 20 | 39 |
| Other | 1 | 0 | 1 |
| Smoking habit, n (%) | 6 (30) | 5 (25) | 11 (27.5) |
| Alcohol consumption, n (%) | 9 (45) | 8 (40) | 17 (42.5) |
| Body mass index (kg/m2) | 26.10 ± 3.84 | 26.79 ± 3.14 | 26.45 ± 3.47 |
| History of diabetes, n (%) | 1 (5) | 1 (5) | 2 (5) |
| Family history of CHD | 3 | 5 | 8 |
| Abnormal blood routine, n (%) | 4/19 (21.1) | 5/20 (25) | 9/39 (23.1) |
| Abnormal urine routine, n (%) | 8/19 (42.1) | 7/20 (35) | 15/39 (38.5) |
| Abnormal stool routine, n (%) | 1/13 (7.7) | 0/16 (0) | 1/29 (3.4) |
| Abnormal liver function, n (%) | 2/19 (10.5) | 1/20 (5) | 3/39 (7.7) |
| Abnormal kidney functions, n (%) | 0/19 (0) | 1/20 (5) | 1/39 (2.6) |
| CCS, n (%) | |||
| 0 | 0 (0) | 0 (0) | 0 (0) |
| I | 10 (50) | 12 (60) | 22 (55) |
| II | 10 (50) | 8 (40) | 18 (45) |
| SAQ | |||
| Physical limitations | 63.89 ± 11.58 | 63.67 ± 13.53 | 63.78 ± 12.43 |
| Anginal stability | 53.75 ± 16.77 | 50.00 ± 18.14 | 51.88 ± 17.35 |
| Anginal frequency | 82.50 ± 15.52 | 81.50 ± 10.89 | 82.00 ± 13.24 |
| Treatment satisfaction | 86.18 ± 11.49 | 80.00 ± 19.59 | 83.09 ± 16.16 |
| Disease perception | 53.75 ± 18.23 | 55.00 ± 25.99 | 54.38 ± 22.17 |
| Echocardiography measurements | |||
| LVEF | 0.64 ± 0.05 | 0.63 ± 0.06 | 0.63 ± 0.06 |
| LVED (mm) | 46.06 ± 3.49 | 48.25 ± 5.30 | 47.21 ± 4.61 |
| Number of vessel stenosis∗ | |||
| Coronary 4-vessel stenosis | 0 (0) | 4 (44.44) | 4 (22.22) |
| Coronary 3-vessel stenosis | 2 (22.22) | 1 (11.11) | 3 (16.67) |
| Coronary 2-vessel stenosis | 3 (33.33) | 2 (22.22) | 5 (27.78) |
| Coronary 1-vessel stenosis | 4 (44.44) | 2 (22.22) | 6 (33.33) |
| Coronary 0-vessel stenosis | 0 (0) | 0 (0) | 0 (0) |
| Medication | |||
| Aspirin | 4 (20) | 9 (45) | 13 (32.5) |
| Clopidogrel | 0 (0) | 0 (0) | 0 (0) |
| Beta-blocker | 3 (15) | 5 (25) | 8 (20) |
| Calcium-channel blocker | 8 (40) | 6 (30) | 14 (35) |
| Angiotensin receptor blockers | 5 (25) | 9 (45) | 14 (35) |
| ACE inhibitor or ARB | 2 (10) | 4 (20) | 6 (15) |
| Nitrate | 3 (15) | 4 (20) | 7 (17.5) |
∗ n = 9.